Treatment for Neuroendocrine Tumors

Phase-Based Estimates
1
Effectiveness
1
Safety
University Hospital Basel, Basel, Switzerland
Eligibility
18+
All Sexes
Eligible conditions
Neuroendocrine Tumors

Study Summary

A Long-term Safety Surveillance Study in Participants Previously Treated With 177Lu-IPN01072

See full description

Treatment Effectiveness

Effectiveness Estimate

1 of 3

Compared to trials

Study Objectives

This trial is evaluating whether Treatment will improve 1 primary outcome and 4 secondary outcomes in patients with Neuroendocrine Tumors. Measurement will happen over the course of During the whole study period (approximately 5 years)..

Year 5
Changes over time in laboratory tests (biochemistry)
Changes over time in laboratory tests (haematology)
Overall survival defined as the time from the first dose of 177Lu-IPN01072 until death from any cause.
Proportion of participants with second primary haematological and non-haematological malignancies.
Proportion of treatment-related adverse events of any grade.

Trial Safety

Safety Estimate

1 of 3

Compared to trials

Trial Design

1 Treatment Groups

Control

This trial requires 38 total participants across 1 different treatment groups

This trial involves a single treatment. Treatment is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.

ControlNo treatment in the control group

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: during the whole study period (approximately 5 years).
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly during the whole study period (approximately 5 years). for reporting.

Closest Location

Eligibility Criteria

This trial is for patients born any sex aged 18 and older. There are 2 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
if able to understand The participant is capable of giving informed consent if they are able to understand. show original
Participants in the study who received at least one infusion of 177Lu-IPN01072 were considered for the primary analysis. show original

Patient Q&A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many people get neuroendocrine tumors a year in the United States?

Add answer

There is about 400 excess deaths from neuroendocrine tumors in the United States each year. Recent findings supports the importance of increased awareness and surveillance for neuroendocrine tumors. It also highlights a public health benefit from expanding access to diagnostic modalities and optimizing therapeutic regimens for these neoplasms.

Unverified Answer

What are common treatments for neuroendocrine tumors?

Add answer

Many endocrine lesions are amenable to hormonal therapy alone or with surgery and/or radiation therapy. In addition, some cancers of the digestive system and pancreas, such as neuroendocrine tumors, can be surgically removed to help manage their symptoms.

Unverified Answer

What causes neuroendocrine tumors?

Add answer

The cause of neuroendocrine tumors is still uncertain. Current theories of their genesis are compatible with the data presented here. These data suggest that a mixture of somatic, genetic, and environmental factors may contribute to the development of these neoplasms.

Unverified Answer

Can neuroendocrine tumors be cured?

Add answer

With proper diagnosis at presentation and management, there is no clear evidence that neuroendocrine tumors can be cured. However, if cure is possible, it will likely involve surgery.

Unverified Answer

What are the signs of neuroendocrine tumors?

Add answer

Symptoms of neuroendocrine tumors can range from nonspecific inapparent symptoms, such as fatigue and nonspecific pain, to more alarming symptoms of heart failure, severe anemia, and severe weight loss in response to chemotherapy. It is important to understand the signs of neuroendocrine tumors to avoid misdiagnosis and lead to delays in patient management.\nsummary: This article describes the physical signs of neuroendocrine tumors. The patient's condition and signs of the tumor are explained.

Unverified Answer

What is neuroendocrine tumors?

Add answer

These tumors can be primary or metastatic and are usually small. Because of their rarity, these tumors are frequently under-diagnosed. They can cause several types of symptoms, including enlargement of the liver and/or an enlarged pituitary. Their treatment can be surgical atrial thrombectomy with/without radiotherapy, as well as medical chemotherapy with/without radiation therapy, and/or targeted therapies.

Unverified Answer

Is treatment typically used in combination with any other treatments?

Add answer

The data in this review can be used to build models of treatment in combination with other treatments in the treatment of patients with neuroendocrine tumors. In each case, the role of treatment with any other treatment remains to be investigated. Clinical trials are ongoing and should be considered.

Unverified Answer

What is the average age someone gets neuroendocrine tumors?

Add answer

Neuroendocrine tumors in children and adolescents tend to be as large as tumors in adults and represent an important and less-recognized disease burden. Given that neuroendocrine tumors rarely cause symptoms unless they are large, new therapies that address symptomatology and quality of life may improve outcomes for children and adolescents with neuroendocrine tumors. Clinical trial design tools should be developed to address these needs.

Unverified Answer

Have there been any new discoveries for treating neuroendocrine tumors?

Add answer

The current treatment options for NETs are limited. Recent studies (http://www.newyork-journal.com/stories/neuroendocrine-tumors) have yielded clues to better understanding cancer treatment and the management of NETs. Current research is focusing on the identification of biomarkers of response to particular treatment regimens, and new therapeutic options that can target tumor cell signaling pathways.

Unverified Answer

Has treatment proven to be more effective than a placebo?

Add answer

The treatment for metastatic pheochromocytoma was superior to treatment with a placebo. The treatment group did not have an advantage compared with patients receiving a sham mifepristone treatment.

Unverified Answer

Have there been other clinical trials involving treatment?

Add answer

Most recent clinical trials were conducted in solid tumors. There were two trials focusing on the treatment of neuroendocrine tumors (NETs), one with sunitinib and another with erlotinib (both tyrosine kinase inhibitors), which were both stopped early by the FDA. Other studies were conducted with targeted therapy, such as immunotherapy and gene therapy targeting KIT, MUC1, or CTLA4 in pancreatic neuroendocrine tumors. Most therapies, however, are in early clinical trials and have not yet been tested systematically for treatment in neuroendocrine tumors. There are, however, a handful of promising approaches.

Unverified Answer

What is the survival rate for neuroendocrine tumors?

Add answer

In patients diagnosed with neuroendocrine tumors, [progression-free survival (PFS) is significantly shorter than that for other tumor types] (median PFS 14.8 months [95% CI, 6.7 to 24.3 months]. When patients are stratified by disease stage, overall survival is significantly shorter after resection of Stage II disease [median PFS 12.34 months (95% CI, 9.16 to 15.54 months)] than after resection of the same disease stage but after surgical resection of stage III disease or after palliative chemotherapy [median PFS 14.41 months (12.6 to 16.31 months)].

Unverified Answer
See if you qualify for this trial
Get access to this novel treatment for Neuroendocrine Tumors by sharing your contact details with the study coordinator.